VANCOUVER, BRITISH COLUMBIA -- (MARKET WIRE) -- May 30, 2007 -- Chemokine Therapeutics Corp. ("Chemokine Therapeutics" or the "Company") (TSX: CTI)(OTCBB: CHKT), a biotechnology company developing chemokine-based therapies to treat cancer, blood disorders, and vascular diseases, announced today that it has filed a registration statement with the U.S. Securities and Exchange Commission and a preliminary short form prospectus with the Canadian securities regulators in connection with an offering of approximately US$25 million of units. Each unit will consist of one share of the Company's common stock and one-half of one common stock purchase warrant. All of the securities will be offered by the Company and will consist of newly issued securities. The Company plans to grant the underwriters a 30-day option to purchase up to an additional US$3.75 million of units to cover over-allotments, if any.
